Ticagrelor Tablet
Product Images NDC 60505-4453

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 60505-4453). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Btl-lbl-90mg-60s.jpg (Btl Lbl 90mg 60s)

Label for Ticagrelor Tablets 90 mg, a human prescription oral tablet product by Apotex Corp. The label indicates a bottle containing 60 film-coated tablets with storage instructions and manufacturer information from Apotex, Toronto, Canada, and Weston, Florida. The label includes dosage guidance to see the package insert and a barcode.*

FDA Label Image

Figure1.jpg (Figure1)

A line graph showing cumulative percentage over days from the first study drug dose for Ticagrelor 90 mg and Clopidogrel groups. The x-axis represents days up to 360, and the y-axis shows cumulative percentage up to 5%. Two curves represent the cumulative % of events for each group, with Ticagrelor consistently higher than Clopidogrel. The graph includes a risk table and event count legend.*

FDA Label Image

Figure10.jpg (Figure10)

A Kaplan-Meier curve graph comparing cumulative event percentages over 360 days after randomization between Ticagrelor 90 mg (solid line) and Clopidogrel (dashed line). The x-axis shows days from randomization, and the y-axis shows cumulative percent. The graph includes patient numbers at risk at various time points.*

FDA Label Image

Figure11.jpg (Figure11)

A forest plot comparing the hazard ratios (HR) and 95% confidence intervals (CI) for Ticagrelor versus Clopidogrel across various patient characteristics and subgroups. The figure plots point estimates with CIs for treatment effects including geographic region, aspirin dose, treatment approach, PCI timing, diabetes history, age, sex, and race, showing relative efficacy between Ticagrelor and Clopidogrel.*

FDA Label Image

Figure12.jpg (Figure12)

A forest plot chart showing hazard ratios (HR) with 95% confidence intervals (CI) comparing Ticagrelor and Clopidogrel effectiveness across different aspirin (ASA) dose groups and regions (US and non-US). The chart includes numeric data for patient counts and events for each subgroup alongside a horizontal axis indicating comparative benefit between Ticagrelor and Clopidogrel.*

FDA Label Image

Figure13.jpg (Figure13)

A cumulative percentage line graph showing event rates over days from randomization comparing Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo groups. Lines represent cumulative event percentages for each group over approximately 1320 days, with corresponding numbers at risk shown below the x-axis and a legend box including patient numbers, events, Kaplan-Meier percentages, hazard ratios, confidence intervals, and p-values.*

FDA Label Image

Figure14.jpg (Figure14)

A forest plot chart showing hazard ratios (HR) with 95% confidence intervals (CI) comparing Ticagrelor versus placebo for various patient characteristics and subgroups in a clinical study. The horizontal axis ranges from 0.5 to 2.0, indicating relative risk with Ticagrelor better on the left and placebo better on the right. Subgroup categories include age group, sex, race, weight group, BMI, geographic region, medical history, type of qualifying myocardial infarction (MI), diabetes, and more.*

FDA Label Image

Figure15.jpg (Figure15)

A line graph comparing the cumulative percentage of events over months from randomization for Ticagrelor and Placebo groups. The x-axis shows time in months up to 54, and the y-axis shows cumulative percentage from 0 to 14%. Two lines represent Ticagrelor (solid) and Placebo (dashed), with event counts and patient numbers at risk displayed along the bottom.*

FDA Label Image

Figure16.jpg (Figure16)

A forest plot comparing hazard ratios (HR) with 95% confidence intervals for various patient characteristics between Ticagrelor and placebo groups. The plot lists characteristics such as age, sex, race, body mass index, geographic region, aspirin dose, and medical history, showing event rates for Ticagrelor and placebo along with HR bars indicating relative effects. The horizontal axis ranges from 0.5 to 2, denoting 'Ticagrelor Better' to 'Placebo Better.'*

FDA Label Image

Figure17.jpg (Figure17)

A Kaplan-Meier survival curve showing cumulative percentage events over days from randomization comparing Ticagrelor 90 mg twice daily versus placebo. The chart includes event counts and percentages for both groups, with a risk table indicating the number of participants at risk over time.*

FDA Label Image

Figure18.jpg (Figure18)

A forest plot chart comparing the hazard ratios (HR) with 95% confidence intervals (CI) for Ticagrelor versus placebo across various patient subgroups. The plot visually displays treatment effects for characteristics such as age, sex, race, weight, BMI, geographic region, diagnosis, and medical history, showing the relative efficacy of Ticagrelor compared to placebo.*

FDA Label Image

Figure2.jpg (Figure2)

A bar chart comparing the percentage of patients who had an event following CABG over several days. Two data sets are presented with solid and hatched bars across days 1 through 8, with numeric values for each day shown below the x-axis. The y-axis measures percentage from 0 to 100%. The chart appears to relate to clinical event occurrence but includes no specific drug information visible in the image.*

FDA Label Image

Figure3.jpg (Figure3)

A cumulative percentage line graph comparing Ticagrelor and Placebo over 54 months from randomization. The graph shows the cumulative percentage on the y-axis and months on the x-axis, with Ticagrelor represented by a solid line and Placebo by a dashed line. A risk table below lists participants at risk over time for both groups.*

FDA Label Image

Figure4.jpg (Figure4)

A Kaplan-Meier cumulative percentage plot comparing Ticagrelor 90 mg twice daily and placebo over approximately 34 days from randomization. The solid line represents Ticagrelor, and the dashed line represents placebo, with numbers at risk displayed below the x-axis for both groups at different time points. The chart shows events per total patients and KM% values in a legend.*

FDA Label Image

Figure5.jpg (Figure5)

A line graph comparing IPA (%) induced by 20 µM ADP over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and placebo. The graph shows Ticagrelor reaching approximately 90% IPA rapidly, Clopidogrel achieving moderate IPA around 50% over time, and placebo showing minimal IPA.*

FDA Label Image

Figure6.jpg (Figure6)

A line graph depicting IPA (%) induced by 20 mcm ADP over time in days on the main chart and hours on the inset. Multiple data series are plotted with different markers, showing IPA changes over 10 days and a detailed view for the first 48 hours. The x-axis is labeled Time (day) for the main chart and Time (hour) for the inset, and the y-axis represents IPA (%) induced by 20 mcm ADP.*

FDA Label Image

Figure7.jpg (Figure7)

A figure titled 'Mean effect and 90% CI' for Ticagrelor showing changes relative to reference across intrinsic factors such as age, gender, ethnicity, renal impairment, end-stage renal disease on hemodialysis, and mild hepatic impairment. The chart uses symbols for pharmacokinetic parameters Cmax (square) and AUC (triangle), with recommendations stating no dose adjustment is required for any factor.*

FDA Label Image

Figure8.jpg (Figure8)

A chart titled 'Mean effect and 90% CI' showing the impact of various interacting drugs on the pharmacokinetics (Cmax and AUC) of Ticagrelor and AR-C124910XX. Drugs listed include strong and moderate CYP3A4 inhibitors, CYP3A4 inducers, aspirin, desmopressin, heparin, enoxaparin, cyclosporine, morphine, and fentanyl. The x-axis shows change relative to reference, and recommendations for dose adjustment or concomitant use are noted on the right.*

FDA Label Image

Figure9.jpg (Figure9)

A chart showing drug interaction effects of various drugs when taken with Ticagrelor at different doses. The chart includes drugs like Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine, with corresponding mean effect and 90% confidence intervals represented by points and horizontal bars. Recommendations on dose adjustments are listed for each interacting drug.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure of ticagrelor, showing its molecular arrangement including functional groups, rings, and fluorine atoms, corresponding to the active pharmaceutical ingredient in ticagrelor tablets by Apotex Corp.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.